SMARCB1 and neoplasm: Whole genome and transcriptome sequencing on seven tumor specimens and three cell lines confirmed SMARCB1 loss by variable mechanisms, but revealed a complex genome with an unexpectedly high mutational rate for a tumor of younger patients.